Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cathepsin B

Cathepsin B

Brief Information

Name:Cathepsin B
Target Synonym:EC 3.4.22,EC:,RECEUP,Cathepsin B,Amyloid Precursor Protein Secretase,Epididymis Secretory Sperm Binding Protein,Cathepsin B1,Cysteine Protease,EC,CPSB,APPS,APP secretase,CTSB
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

Cathepsin B MALS images

The purity of Mouse Cathepsin B, His Tag (Cat. No. CTB-M52H9) is more than 90% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.

Cathepsin B MALS images

The purity of Human Cathepsin B, His Tag (Cat. No. CTB-H5222) is more than 90% and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.

Synonym Name



Cathepsin B (CTSB) is also known as APP secretase (APPS) and CPSB, is an enzymatic protein belonging to the peptidase C1 family. Cathepsin B / CTSB is synthesized as a preproenzyme. Following removal of the signal peptide, the inactive proenzyme undergoes further modifications including removal of the pro region to result in the active enzyme. The catalytic activity of Cathepsin B / APPS contains: Hydrolysis of proteins with broad specificity for peptide bonds; Preferentially cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates (thus differing from cathepsin L); In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. As a thiol protease, cathepsin B / CPSB is believed to participate in intracellular degradation and turnover of proteins and has also been implicated in tumor invasion and metastasis. Overexpression of cathepsin B has been associated with esophageal adenocarcinoma and other tumors.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Osugacestat AL-101(BMS); BMS-906024 Phase 2 Clinical Bristol-Myers Squibb Company, Glaxosmithkline Plc Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message